Cargando…

Blocking insulin-like growth factor 1 receptor signaling pathway inhibits neuromuscular junction regeneration after botulinum toxin-A treatment

Botulinum toxin-A (BTX) administration into muscle is an established treatment for conditions with excessive muscle contraction. However, botulinum therapy has short-term effectiveness, and high-dose injection of BTX could induce neutralizing antibodies against BTX. Therefore, prolonging its effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishihara, Hiroki, Otani, Yoshinori, Tanaka, Kazuki, Miyajima, Hisao, Ngo, Huy Xuan, Fujitani, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505167/
https://www.ncbi.nlm.nih.gov/pubmed/37717026
http://dx.doi.org/10.1038/s41419-023-06128-w
_version_ 1785106863102099456
author Ishihara, Hiroki
Otani, Yoshinori
Tanaka, Kazuki
Miyajima, Hisao
Ngo, Huy Xuan
Fujitani, Masashi
author_facet Ishihara, Hiroki
Otani, Yoshinori
Tanaka, Kazuki
Miyajima, Hisao
Ngo, Huy Xuan
Fujitani, Masashi
author_sort Ishihara, Hiroki
collection PubMed
description Botulinum toxin-A (BTX) administration into muscle is an established treatment for conditions with excessive muscle contraction. However, botulinum therapy has short-term effectiveness, and high-dose injection of BTX could induce neutralizing antibodies against BTX. Therefore, prolonging its effects could be beneficial in a clinical situation. Insulin-like growth factor-1 receptor (IGF1R) and its ligands, insulin-like growth factor (IGF) -I and II, regulate the physiological and pathological processes of the nervous system. It has been suggested that IGF1R is involved in the process after BTX administration, but the specific regeneration mechanism remains unclear. Therefore, this study aimed to determine how inhibition of IGF1R signaling pathway affects BTX-induced muscle paralysis. The results showed that anti-IGF1R antibody administration inhibited the recovery from BTX-induced neurogenic paralysis, and the synaptic components at the neuromuscular junction (NMJ), mainly post-synaptic components, were significantly affected by the antibody. In addition, the wet weight or frequency distribution of the cross-sectional area of the muscle fibers was regulated by IGF1R, and sequential antibody administration following BTX treatment increased the number of Pax7(+)-satellite cells in the gastrocnemius (GC) muscle, independent of NMJ recovery. Moreover, BTX treatment upregulated mammalian target of rapamycin (mTOR)/S6 kinase signaling pathway, HDAC4, Myog, Fbxo32/MAFbx/Atrogin-1 pathway, and transcription of synaptic components, but not autophagy. Finally, IGF1R inhibition affected only mTOR/S6 kinase translational signaling in the GC muscle. In conclusion, the IGF1R signaling pathway is critical for NMJ regeneration via specific translational signals. IGF1R inhibition could be highly beneficial in clinical practice by decreasing the number of injections and total dose of BTX due to the prolonged duration of the effect.
format Online
Article
Text
id pubmed-10505167
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-105051672023-09-18 Blocking insulin-like growth factor 1 receptor signaling pathway inhibits neuromuscular junction regeneration after botulinum toxin-A treatment Ishihara, Hiroki Otani, Yoshinori Tanaka, Kazuki Miyajima, Hisao Ngo, Huy Xuan Fujitani, Masashi Cell Death Dis Article Botulinum toxin-A (BTX) administration into muscle is an established treatment for conditions with excessive muscle contraction. However, botulinum therapy has short-term effectiveness, and high-dose injection of BTX could induce neutralizing antibodies against BTX. Therefore, prolonging its effects could be beneficial in a clinical situation. Insulin-like growth factor-1 receptor (IGF1R) and its ligands, insulin-like growth factor (IGF) -I and II, regulate the physiological and pathological processes of the nervous system. It has been suggested that IGF1R is involved in the process after BTX administration, but the specific regeneration mechanism remains unclear. Therefore, this study aimed to determine how inhibition of IGF1R signaling pathway affects BTX-induced muscle paralysis. The results showed that anti-IGF1R antibody administration inhibited the recovery from BTX-induced neurogenic paralysis, and the synaptic components at the neuromuscular junction (NMJ), mainly post-synaptic components, were significantly affected by the antibody. In addition, the wet weight or frequency distribution of the cross-sectional area of the muscle fibers was regulated by IGF1R, and sequential antibody administration following BTX treatment increased the number of Pax7(+)-satellite cells in the gastrocnemius (GC) muscle, independent of NMJ recovery. Moreover, BTX treatment upregulated mammalian target of rapamycin (mTOR)/S6 kinase signaling pathway, HDAC4, Myog, Fbxo32/MAFbx/Atrogin-1 pathway, and transcription of synaptic components, but not autophagy. Finally, IGF1R inhibition affected only mTOR/S6 kinase translational signaling in the GC muscle. In conclusion, the IGF1R signaling pathway is critical for NMJ regeneration via specific translational signals. IGF1R inhibition could be highly beneficial in clinical practice by decreasing the number of injections and total dose of BTX due to the prolonged duration of the effect. Nature Publishing Group UK 2023-09-16 /pmc/articles/PMC10505167/ /pubmed/37717026 http://dx.doi.org/10.1038/s41419-023-06128-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ishihara, Hiroki
Otani, Yoshinori
Tanaka, Kazuki
Miyajima, Hisao
Ngo, Huy Xuan
Fujitani, Masashi
Blocking insulin-like growth factor 1 receptor signaling pathway inhibits neuromuscular junction regeneration after botulinum toxin-A treatment
title Blocking insulin-like growth factor 1 receptor signaling pathway inhibits neuromuscular junction regeneration after botulinum toxin-A treatment
title_full Blocking insulin-like growth factor 1 receptor signaling pathway inhibits neuromuscular junction regeneration after botulinum toxin-A treatment
title_fullStr Blocking insulin-like growth factor 1 receptor signaling pathway inhibits neuromuscular junction regeneration after botulinum toxin-A treatment
title_full_unstemmed Blocking insulin-like growth factor 1 receptor signaling pathway inhibits neuromuscular junction regeneration after botulinum toxin-A treatment
title_short Blocking insulin-like growth factor 1 receptor signaling pathway inhibits neuromuscular junction regeneration after botulinum toxin-A treatment
title_sort blocking insulin-like growth factor 1 receptor signaling pathway inhibits neuromuscular junction regeneration after botulinum toxin-a treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505167/
https://www.ncbi.nlm.nih.gov/pubmed/37717026
http://dx.doi.org/10.1038/s41419-023-06128-w
work_keys_str_mv AT ishiharahiroki blockinginsulinlikegrowthfactor1receptorsignalingpathwayinhibitsneuromuscularjunctionregenerationafterbotulinumtoxinatreatment
AT otaniyoshinori blockinginsulinlikegrowthfactor1receptorsignalingpathwayinhibitsneuromuscularjunctionregenerationafterbotulinumtoxinatreatment
AT tanakakazuki blockinginsulinlikegrowthfactor1receptorsignalingpathwayinhibitsneuromuscularjunctionregenerationafterbotulinumtoxinatreatment
AT miyajimahisao blockinginsulinlikegrowthfactor1receptorsignalingpathwayinhibitsneuromuscularjunctionregenerationafterbotulinumtoxinatreatment
AT ngohuyxuan blockinginsulinlikegrowthfactor1receptorsignalingpathwayinhibitsneuromuscularjunctionregenerationafterbotulinumtoxinatreatment
AT fujitanimasashi blockinginsulinlikegrowthfactor1receptorsignalingpathwayinhibitsneuromuscularjunctionregenerationafterbotulinumtoxinatreatment